“It Has Been a Huge Disappointment”

Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer put under the microscope. Cramer discussed it while highlighting the performance of healthcare stocks. He said:

“Some of these healthcare stocks seem played out already to you, perhaps. I mean, Merck was up 7% just today. Charitable holding Danaher also leaped more than 7%. But these stocks have been down so long, they look up to me. I believe they’ve got a lot more upside before they run out of steam. My Charitable Trust owns Danaher, and it has been a huge disappointment. It needs to demonstrate it can capitalize off of all the new drug companies coming public right now, or it will go back to the 180s.”

A man in black suit holding a tablet looks at stock market data on a monitor. Photo by Tima Miroshnichenko on Pexels

Danaher Corporation (NYSE:DHR) develops medical, life sciences, biotechnology, and diagnostic products, including bioprocessing technologies, lab equipment, genomic tools, and clinical instruments. Cramer mentioned the stock during the July 24 episode and said:

“Now, we bought this one in early 2022… I expected the business to stabilize and the stock to make a comeback like that. But for one reason after another, Danaher never really found its footing…

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.